

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Proposed Single Technology Appraisal (STA)**

**Serelaxin for treating acute decompensation of heart failure**

**Provisional matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Novartis Pharmaceuticals (serelaxin)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Heart</li> <li>• Afiya Trust</li> <li>• Arrhythmia Alliance</li> <li>• Black Health Agency</li> <li>• British Cardiac Patients Association</li> <li>• Cardiomyopathy Association</li> <li>• Equalities National Council</li> <li>• Heart Care Partnership (UK)</li> <li>• Independent Age</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Network of Sikh Organisations</li> <li>• Somerville Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Nursing in Cardiac Care</li> <li>• British Association for Service to the Elderly</li> <li>• British Cardiovascular Intervention Society (BCIS)</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Nuclear Cardiology Society</li> <li>• British Society for Cardiovascular Imaging</li> <li>• British Society for Heart Failure</li> <li>• College of Emergency Medicine</li> <li>• Heart Rhythm UK</li> <li>• Primary Care Cardiovascular Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (furosemide)</li> <li>• Actavis UK (furosemide)</li> <li>• Almus (bumetanide)</li> <li>• Amdipharm Mercury (furosemide)</li> <li>• Arrow Generics (bumetanide, furosemide)</li> <li>• Aurobindo Pharma (furosemide)</li> <li>• Chanelle Medical UK (furosemide)</li> <li>• Focus Pharmaceuticals (furosemide)</li> <li>• Hameln ((furosemide)</li> <li>• Leo Pharma (bumetanide)</li> <li>• Meda Pharmaceuticals UK (torasemide)</li> <li>• Mylan UK (furosemide)</li> <li>• Orion Pharma (furosemide)</li> </ul>

## Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science &amp; Technology</li> <li>• UK Health Forum (formerly National Heart Forum)</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Oxfordshire CCG</li> <li>• NHS South Gloucestershire CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Pinewood Healthcare (furosemide)</li> <li>• Ranbaxy UK (furosemide)</li> <li>• Rosemont Pharmaceuticals (furosemide)</li> <li>• Sanofi ((furosemide)</li> <li>• Sandoz (furosemide)</li> <li>• Teva UK (bumetanide, furosemide)</li> <li>• Winthrop Pharmaceuticals (furosemide)</li> <li>• Wockhardt UK (furosemide)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research [BCS affiliated]</li> <li>• Cardiac and Cardiology Research Dept, Barts</li> <li>• Central Cardiac Audit Database</li> <li>• Cochrane Heart Group</li> <li>• European Council for Cardiovascular Research</li> <li>• Health Research Authority</li> <li>• Heart Research UK</li> <li>• National Heart Research Fund</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> <li>• Wellcome Trust - Cardiovascular Research Initiative</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Chronic Conditions</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales NHS Trust</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.